01 August 2008 22:48 [Source: ICIS news]
By Feliza Mirasol
NEW YORK (ICIS news)--American Peptide Company will establish a stronger foothold in the global pharmaceutical and biotechnology markets following its acquisition by Otsuka Chemical, American Peptide’s president said on Friday.
“This is an important deal for Otsuka Chemical and APC. We will continue to be a strong peptide CMO [contract manufacturing organisation],” said Takahiro Ogata, president and chief operating officer of American Peptide.
Under Otsuka Chemical, American Peptide will have access to expanded global networking opportunities and more financial resources for its production and manufacturing facilities, Ogata added.
On Wednesday, American Peptide announced that its parent company, Ito Life Sciences, would be acquired by Otsuka Chemical for an undisclosed amount. The deal is expected to close on 1 September.
The acquisition was timely, Ogata said. American Peptide is growing at around 15-20%/year and its customers are growing in terms of both volume and scale, he added.
American Peptide carries its pharmaceutical and biotechnology customers from preclinical through commercial manufacturing stages.
American Peptide is in the midst of expanding its cGMP (current good manufacturing practices) manufacturing facility in ?xml:namespace>
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections